Omeros Corp. (OMER)

13.85
0.50 3.50
NASDAQ : Health Technology
Prev Close 14.35
Open 14.46
Day Low/High 13.77 / 14.65
52 Wk Low/High 8.36 / 27.00
Volume 635.24K
Avg Volume 572.50K
Exchange NASDAQ
Shares Outstanding 49.01M
Market Cap 641.53M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Omeros Corporation Appoints Thomas F. Bumol, Ph.D., To Board Of Directors

Omeros Corporation Appoints Thomas F. Bumol, Ph.D., To Board Of Directors

Omeros Corporation (NASDAQ: OMER) today announced the appointment of Thomas F. Bumol, Ph.

Omeros Finalizes With FDA Clinical Plan For OMS721 Approval In IgA Nephropathy

Omeros Finalizes With FDA Clinical Plan For OMS721 Approval In IgA Nephropathy

Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.

Omeros Corporation Announces Record High Quarterly Revenue Results For The Fourth Quarter 2018

Omeros Corporation Announces Record High Quarterly Revenue Results For The Fourth Quarter 2018

Omeros Corporation (Nasdaq: OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018.

First Week Of OMER August 16th Options Trading

First Week Of OMER August 16th Options Trading

Investors in Omeros Corp saw new options become available this week, for the August 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 221 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Omeros Becomes Oversold (OMER)

Omeros Becomes Oversold (OMER)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Noteworthy Thursday Option Activity: OMER, PTLA, BGS

Noteworthy Thursday Option Activity: OMER, PTLA, BGS

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp , where a total of 6,181 contracts have traded so far, representing approximately 618,100 underlying shares. That amounts to about 103% of OMER's average daily trading volume over the past month of 600,365 shares.

Omeros Establishes Independent Academic Leadership Committee For Its OMS721 Phase 3 Clinical Program In IgA Nephropathy

Omeros Establishes Independent Academic Leadership Committee For Its OMS721 Phase 3 Clinical Program In IgA Nephropathy

Omeros Corporation (Nasdaq: OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for OMS721 in immunoglobulin A (IgA) nephropathy.

Omeros Announces Research Collaboration With University Of Cambridge

Omeros Announces Research Collaboration With University Of Cambridge

Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR).

Omeros Announces Clinical Strategy To Accelerate Pediatric Development Of OMS721 For The Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Omeros Announces Clinical Strategy To Accelerate Pediatric Development Of OMS721 For The Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

Omeros Corporation (Nasdaq: OMER) today announced that it has submitted a pediatric investigational plan (PIP) for the use of OMS721 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) to the European...

Omeros Announces Additions To Senior Management Team

Omeros Announces Additions To Senior Management Team

Omeros Corporation (Nasdaq: OMER) today announced that it hired two new senior management team members - Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.

Omeros Announces Pricing Of $210 Million Offering Of Convertible Senior Notes Due 2023

Omeros Announces Pricing Of $210 Million Offering Of Convertible Senior Notes Due 2023

Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced the pricing of an offering of $210 million aggregate principal amount of its 6.

Omeros Announces Proposed $210 Million Offering Of Convertible Senior Notes Due 2023

Omeros Announces Proposed $210 Million Offering Of Convertible Senior Notes Due 2023

SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the...

Omeros Corporation Reports Third Quarter 2018 Financial Results

Omeros Corporation Reports Third Quarter 2018 Financial Results

Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2018, which include: 3Q 2018 total and OMIDRIA ® revenues were $4.

Omeros Corporation To Announce Third Quarter 2018 Financial Results On November 9, 2018

Omeros Corporation To Announce Third Quarter 2018 Financial Results On November 9, 2018

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens.

Reflecting on 9/11: Cramer's 'Mad Money' Recap (Tuesday 9/11/18)

Reflecting on 9/11: Cramer's 'Mad Money' Recap (Tuesday 9/11/18)

Jim Cramer says he believes we are today better prepared for both the terror and the financial attacks that America endured on 9/11.

Cypress Semiconductor, Omeros, Zuora: 'Mad Money' Lightning Round

Cypress Semiconductor, Omeros, Zuora: 'Mad Money' Lightning Round

Jim Cramer weighs in on Cypress Semiconductor, Omeros, Zuora, Kemet, Leidos, Raytheon, and Skyworks Solutions.

FDA Grants Orphan Drug Designation To Omeros' OMS721 For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

FDA Grants Orphan Drug Designation To Omeros' OMS721 For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

Omeros Corporation (NASDAQ:OMER) today announced that OMS721 has received orphan drug designation from the U.

Relative Strength Alert For Omeros

Relative Strength Alert For Omeros

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Omeros Corporation Announces Additional Positive Data For OMS721 In IgA Nephropathy

Omeros Corporation Announces Additional Positive Data For OMS721 In IgA Nephropathy

Omeros Corporation (NASDAQ: OMER) today announced positive data from the company's ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases.

Omeros Corporation Announces Reinstatement Of Pass-Through Status For OMIDRIA®

Omeros Corporation Announces Reinstatement Of Pass-Through Status For OMIDRIA®

Omeros Corporation (NASDAQ: OMER) announced that reinstatement of separate payment by the Centers for Medicare and Medicaid Services (CMS) under the pass-through program for the company's cataract surgery drug OMIDRIA ® (phenylephrine and ketorolac...

Omeros To Present At The 2018 Cantor Global Healthcare Conference

Omeros To Present At The 2018 Cantor Global Healthcare Conference

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.

Omeros To Present At The Morgan Stanley Global Healthcare Conference

Omeros To Present At The Morgan Stanley Global Healthcare Conference

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

European Commission Designates OMS721 As An Orphan Medicinal Product For Treatment In Hematopoietic Stem Cell Transplantation

European Commission Designates OMS721 As An Orphan Medicinal Product For Treatment In Hematopoietic Stem Cell Transplantation

Omeros Corporation (Nasdaq: OMER) today announced that the European Commission (EC) has adopted a decision designating OMS721 as an Orphan Medicinal Product in the European Union (EU) for treatment in hematopoietic stem cell transplantation (HSCT).

Notable Friday Option Activity: OMER, SQ, VTL

Notable Friday Option Activity: OMER, SQ, VTL

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp , where a total of 2,615 contracts have traded so far, representing approximately 261,500 underlying shares. That amounts to about 58.2% of OMER's average daily trading volume over the past month of 449,185 shares.

Omeros To Present At The 2018 Wedbush PacGrow Healthcare Conference

Omeros To Present At The 2018 Wedbush PacGrow Healthcare Conference

Omeros Corporation (NASDAQ: OMER), today announced that Gregory A. Demopulos, M.

Omeros Corporation Reports Second Quarter 2018 Financial Results

Omeros Corporation Reports Second Quarter 2018 Financial Results

Omeros Corporation (NASDAQ: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2018, which include: 2Q 2018 total and OMIDRIA ® revenues were $1.

Omeros Corporation To Announce Second Quarter 2018 Financial Results On August 9, 2018

Omeros Corporation To Announce Second Quarter 2018 Financial Results On August 9, 2018

Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its second quarter 2018 financial results for the period ended June 30, 2018, on Thursday, August 9, 2018, after the market closes.

TheStreet Quant Rating: D- (Sell)